v3 Template
N

NexImmune, Inc.

Biotechnology / Healthcare ~700 employees
Founded
--
Employees (Est.)
~700
35 leaders known
Total Funding
$7.3M
Funding Rounds
2
Last Funding
2024-02-06

About NexImmune, Inc.

NexImmune is a rapidly growing leader in the field of antigen-directed immunotherapies, focused on developing novel technology to orchestrate targeted cell-mediated immune responses across a broad range of diseases. Their vision is to conquer cancer and life-threatening immune-mediated conditions by directing natural, disease-specific immune responses using their proprietary Artificial Immune Modulation (AIM) nanotechnology platform.

Products & Services

AIM™ NT Platform:A nanotechnology platform that uses natural biology to deliver specific instructions to T cells for targeted immune responses.
AIM™ ACT Adoptive Cellular Therapy:A therapy that employs AIM nanoparticles to direct T cell-mediated immune responses for treating diseases like cancer.
AIM™ INJ Direct Injection:A direct injection method using AIM nanoparticles to customize immune responses for various diseases.

Specialties

Antigen-directed immunotherapies T cell-mediated immune responses Nanotechnology (Artificial Immune Modulation - AIM) Cancer treatment Autoimmune disorders Infectious diseases

Funding History

Debug: View Raw Funding Data
# Type Amount Fields Date Fields Investors
1 RT: Registered Direct Offering
T: -
FT: Registered Direct Offering
A: 3670000
MR: -
FA: $3.67 million
FAN: 3670000
D: 2024-02-06
FD: 2024-02-06
1 investors
2 RT: Registered Direct Offering
T: -
FT: Registered Direct Offering
A: 3670000
MR: -
FA: $3.67 million
FAN: 3670000
D: 2024-02-02
FD: 2024-02-02
1 investors
Registered Direct Offering Latest
2024-02-06
$3.7M
1 investor (Pro only)
Registered Direct Offering 2024-02-02
$3.7M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active

View 3 more growth metrics with Pro

Unlock All Metrics
Mock Up

Team & Leadership

R

Rajesh L

Author

J

Josh Comolli

Author at Neximmune

G

Gerald (Jerry) Nepom

Director of the Immune Tolerance Network and Professor of Immunology

J

Jeffrey Cohen

Chief of the Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases at NIH

D

David Hafler

William S. and Lois Stiles Edgerly Professor of Neurology and Chairman, Department of Neurology, Yale University School of Medicine

K

Kevan Herold

C.N.H., Long Professor of Immunobiology and of Medicine (Endocrinology)

View 32 more team members with Pro

Unlock Full Team Directory

Recent News

NexImmune, Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Read more →

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Read more →

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Read more →

View 2 more news articles with Pro

Unlock Full News Feed
Mock Up

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Industries
Biotechnology / Healthcare
Company Size
~700 employees (est.)

Similar Companies

Discover AI-powered company recommendations based on industry, funding, and team profiles.

Upgrade to Pro

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro